Evidence-based recommendations on irreversible electroporation for treating primary liver cancer. This involves a process that uses electrical pulses to kill cancer cells.
Is this guidance up to date?
We checked this guidance in June 2019 and we are updating it. See the guideline in development page for progress on the update.
Guidance development process
Percutaneous approach with image guidance:
J12.8 Other specified other therapeutic percutaneous operations on liver
Y12.3 Electrochemotherapy to lesion of organNOC
Y53.- Approach to organ under image control
In addition ICD-10 code C22.9 Malignant neoplasm of liver, unspecified is assigned.
The NHS Classifications Service has advised NICE that currently these are the most suitable OPCS-4 codes to describe this procedure. The OPCS-4 classification is designed to categorise procedures for analysis and it is not always possible to identify a procedure uniquely.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.